Taxotere approved for prostate cancer
Executive Summary
Aventis' Taxotere (docetaxel) adds indication for treatment of hormone refractory prostate cancer in combination with prednisone May 19. Revised 1labeling includes data from 335 patients showing median survival advantage of 2.4 months versus mitoxantrone (Amgen/OSI's Novantrone). Taxotere is first drug to show survival benefit in that population, FDA says. Aventis is also investigating Taxotere as first-line prostate cancer therapy...